Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

被引：0
|
作者：
Gizem Oner
Semen Önder
Hüseyin Karatay
Naziye Ak
Mustafa Tükenmez
Mahmut Müslümanoğlu
Abdullah İğci
Ahmet Dincçağ
Vahit Özmen
Adnan Aydiner
Ekrem Yavuz
Neslihan Cabioğlu
机构：
[1] Istanbul University,Department of General Surgery, Istanbul Faculty of Medicine
[2] Antwerp University Hospital,Multidisciplinary Oncologic Centre Antwerp (MOCA)
[3] University of Antwerp,Center for Oncological Research (CORE)
[4] Istanbul University,Department of Pathology, Istanbul Faculty of Medicine
[5] Istanbul University,Department of Medical Oncology, Institute of Oncology
来源：
World Journal of Surgical Oncology | / 19卷
关键词：
Triple-negative breast cancer; PD-L1 expression; Prognosis; Neoadjuvant chemotherapy response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
    Oner, Gizem
    Onder, Semen
    Karatay, Huseyin
    Ak, Naziye
    Tukenmez, Mustafa
    Muslumanoglu, Mahmut
    Igci, Abdullah
    Dinccag, Ahmet
    Ozmen, Vahit
    Aydiner, Adnan
    Yavuz, Ekrem
    Cabioglu, Neslihan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [2] Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
    Gizem Oner
    Semen Önder
    Hüseyin Karatay
    Naziye Ak
    Mustafa Tükenmez
    Mahmut Müslümanoğlu
    Abdullah İğci
    Ahmet Dincçağ
    Vahit Özmen
    Adnan Aydiner
    Ekrem Yavuz
    Neslihan Cabioğlu
    World Journal of Surgical Oncology, 21
  • [3] Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy (vol 19, 264, 2021)
    Oner, Gizem
    Onder, Semen
    Karatay, Huseyin
    Ak, Naziye
    Tukenmez, Mustafa
    Muslumanoglu, Mahmut
    Igci, Abdullah
    Dinccag, Ahmet
    Ozmen, Vahit
    Aydiner, Adnan
    Yavuz, Ekrem
    Cabioglu, Neslihan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [4] Prospective genomic and PD-L1 profiling of patients with residual triple negative breast cancer after neoadjuvant chemotherapy
    Irie, Hanna Yoko
    Schmidt, Paul
    Port, Elisa
    Berger, Natalie
    Klein, Paula
    Kinoshita, Yayoi
    Soto, Alan
    Pisapati, Kereeti
    Couri, Ronald
    Kolodka, Olivia
    Arib, Hanane
    Sebra, Robert
    Donovan, Michael J.
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
  • [6] PD-L1 Expression in Triple-Negative Breast Cancer
    Mittendorf, Elizabeth A.
    Philips, Anne V.
    Meric-Bernstam, Funda
    Qiao, Na
    Wu, Yun
    Harrington, Susan
    Su, Xiaoping
    Wang, Ying
    Gonzalez-Angulo, Ana M.
    Akcakanat, Argun
    Chawla, Akhil
    Curran, Michael
    Hwu, Patrick
    Sharma, Padmanee
    Litton, Jennifer K.
    Molldrem, Jeffrey J.
    Alatrash, Gheath
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (04) : 361 - 370
  • [7] Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
    Ilieva, Nevena
    Pencheva, Mina
    Hadzhiev, Hristo
    Tashkova, Desislava
    Daskalova, Elena
    Georgiev, Petar
    Genova, Sylvia
    DIAGNOSTICS, 2024, 14 (23)
  • [8] PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
    Grandal, Beatriz
    Mangiardi-Veltin, Manon
    Laas, Enora
    Lae, Marick
    Meseure, Didier
    Bataillon, Guillaume
    El-Alam, Elsy
    Darrigues, Lauren
    Dumas, Elise
    Daoud, Eric
    Vincent-Salomon, Anne
    Talagrand, Laure-Sophie
    Pierga, Jean-Yves
    Reyal, Fabien
    Hamy, Anne-Sophie
    CANCERS, 2021, 13 (04) : 1 - 17
  • [9] High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.
    Oner, Gizem
    Onder, Semen
    Karatay, Huseyin
    Tukenmez, Mustafa
    Muslumanoglu, Mahmut
    Igci, Abdullah
    Dinccag, Ahmet
    Ozmen, Vahit
    Aydiner, Adnan
    Yavuz, Ekrem
    Cabioglu, Neslihan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
    Ahmed, Fahad Shabbir
    Gaule, Patricia
    McGuire, John
    Patel, Katir
    Blenman, Kim
    Pusztai, Lajos
    Rimm, David L.
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5456 - 5461
12345